Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xuming Tongmai Tang is a Traditional Chinese Medicine (TCM) decoction developed or utilized by the **Chongqing Hospital of Traditional Chinese Medicine** for the treatment of **acute ischemic stroke (AIS)**. It is typically administered as part of the "Tongmai Xingshen" method, which integrates the herbal decoction with blood-pricking brain-awakening therapy. The formula is specifically evaluated for its efficacy and safety when added after reperfusion therapy (such as intravenous thrombolysis or mechanical thrombectomy) in patients who have undergone blood flow recanalization. As a multi-herb TCM formulation, it is intended to improve neurological function, mitigate reperfusion injury, and promote recovery through multi-target mechanisms likely involving anti-inflammatory and microcirculation-improving properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xuming Tongmai Tang.